CDC Enhanced Antibody Products

CDC Enhanced Antibody: A Promising Therapeutic for Cancer Therapy

Complement-dependent cytotoxicity (CDC) is an effective mode of action for therapeutic antibodies. These antibodies can more efficiently begin the complement cascade by boosting C1q binding, resulting in greater cell lysis and therapeutic efficiency. By leveraging the complement system, CDC-enhanced antibodies can improve the treatment of cancer and other diseases. As a result, engineering antibodies with enhanced CDC offers great potential for generating more powerful and effective antibody-based therapeutics, notably those for cancer and autoimmune illnesses.

The Advantages of CDC Enhanced Antibody

CDC-enhanced antibodies offer several advantages:

• Enhanced potency to effectively trigger the complement cascade, leading to increased cell lysis and improved therapeutic efficacy.
• Broader therapeutic potential to be applied to a wider range of diseases, including cancers and autoimmune disorders.
• Synergy with other effector mechanisms to achieve a more potent and comprehensive therapeutic response.
• Improved efficacy against cancer cells that have developed resistance to other therapies, such as those that downregulate ADCC-mediating Fc receptors.

Fig.1 The complement pathways overview (classical and alternative).^1,3

CDC Enhanced Antibody Expression and Purification at Creative Biolabs

Leveraging our antibody production platform, Creative Biolabs provides a widely suitable CDC enhanced antibody expression and purification service to support global customers' therapeutic efficacy-enhancing projects. Our advanced technologies enable us to optimize antibody design, expression, and purification to maximize complement-dependent cytotoxicity (CDC) activity. By precisely modifying the Fc region (CH2 domain), we can significantly increase C1q binding and subsequent CDC.

In addition, our state-of-the-art eukaryotic cell expression system ensures the efficient production of functional CDC-enhanced antibodies. Moreover, we also provide specialized functional validation services to evaluate CDC-enhanced antibodies. Our rigorous quality control measures guarantee the activity, potency, and CDC enhancement of the final product. If you have any specific demands, our experienced team can customize the whole service process, enabling high-quality CDC-enhanced antibody delivery promptly.

Fig.2 Our service process.

Amino Acid Exchanges for CDC Enhanced Antibody Production

The CH2 domain of IgG antibodies, particularly residues within the C1q and FcγR binding sites, plays a crucial role in complement-dependent cytotoxicity (CDC). By strategically engineering amino acid substitutions in this region, researchers have effectively enhanced CDC activity. Here are some validated examples of amino acid substitutions (alone or in combination) that have been effective in enhancing CDC, such as S267E amino acid substitutions.

State-of-the-art Eukaryotic Cell Expression Systems

Creative Biolabs specializes in producing high-quality, CDC-enhanced antibodies using advanced eukaryotic cell expression technologies. We leverage the power of mammalian cell lines, such as HEK293 and CHO cells, to ensure accurate post-translational modifications, critical for optimal antibody function. For simpler antibodies, we also offer the flexibility of insect cell line expression systems, providing a rapid and cost-effective solution for high-yield production.

• HEK293 cells
• CHO cells
• Sf9 insect cells

Features of Our CDC Enhanced Antibody Expression and Purification Service

• Adhering to industry regulatory specifications for quality and safety.
• Tailored eukaryotic cell expression systems for optimal protein production.
• High-quality, high-yield, and scalable production of CDC-enhanced antibodies.
• Flexible and customized service solutions.

Case Show

Summary: This study engineered anti-CD19 antibodies with amino acid exchanges to enhance CDC and evaluated these antibodies' ability to induce CDC. The result demonstrated the engineered antibodies exhibited increased C1q binding affinity, leading to superior CDC induction compared to unmodified anti-CD19 antibodies.

Fig.3 The evaluation of engineered CD19 antibodies on C1q binding and CDC induction.^2,3

As a leading provider of antibody solutions, Creative Biolabs is dedicated to accelerating drug discovery and preclinical research. Our expertise in CDC-enhanced antibody expression and purification ensures the delivery of high-quality antibodies that meet the stringent demands of modern biomedical research. To learn more about our CDC enhanced antibody products and production service, please contact us immediately.

For Research Use Only. Not For Clinical Use.